Matthias H. Busch

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

Alexander P. J. Vlaar, Sanne de Bruin, Matthias H. Busch et al. · The Lancet Rheumatology · 2020 · 200 citations · Full text

Life Sciences, Immunology, Infectious Diseases +8

Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Alexander P. J. Vlaar, Martin Witzenrath, Pieter van Paassen et al. · The Lancet Respiratory Medicine · 2022 · 142 citations · Full text

Medicine, Infectious Diseases, Pharmacotherapy +12

Diversity in prevalence and characteristics of ESBL/pAmpC producing E. coli in food in Germany

Annemarie Kaesbohrer, Karin Lebl, Alexandra Irrgang et al. · Veterinary Microbiology · 2019 · 127 citations · Full text

Agriculture, Food Science, Microbiology +16

Renal Recovery for Patients with ANCA-Associated Vasculitis and Low eGFR in the ADVOCATE Trial of Avacopan

Frank B. Cortazar, John L. Niles, David Jayne et al. · Kidney International Reports · 2023 · 85 citations · Full text

Medicine, Internal Medicine, Nephrology +16

Urinary Soluble CD163 and Disease Activity in Biopsy-Proven ANCA-Associated Glomerulonephritis

Joop P. Aendekerk, Sjoerd A.M.E.G. Timmermans, Matthias H. Busch et al. · Clinical Journal of the American Society of Nephrology · 2020 · 40 citations · Full text

Medicine, Nephrology, Pathology +17